HarryADrabkinMD

Professor of Medicine & Gilbreth Chair in Clinical Oncology Director, Division of Hematology/Oncology Medical University of South Carolina

Join to view full profile

Dr. Drabkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Drabkin's full profile

Already have an account?

Office
985 S Pearl St
Denver, CO 80209

Education & Training

University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1977 - 1980
University of Kansas School of MedicineClass of 1977

Certifications & Licensure

CO State Medical License 1980 - 2025
MT State Medical License 2021 - 2025
AK State Medical License 2023 - 2024
OH State Medical License 1978 - 2019
SC State Medical License 2007 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Phase II Study of AS1411 in Renal Cell Carcinoma Start of enrollment: 2008 Aug 01
Unknown status
Phase 2
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

5 citations
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Anastasios Dimou, Cecile Nasarre, Yuri K. Peterson, Rose Pagano, Monika Gooz
The Journal of Thoracic and Cardiovascular Surgery. 2021-08-01
97 citations
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera
Journal of Clinical Oncology. 2018-01-08
4 citations
A triad of NRP2, DLX and p53 proteins in lung cancer metastasis.
Harry A. Drabkin, Julia Starkova, Robert M. Gemmill
Oncotarget. 2017-10-26

Grant Support

SEMA3F And ZEB1 In Lung Cancer: Therapy And Target Gene DiscoveryNational Cancer Institute2008–2011
DNA Sequencing &Analysis CoreNational Cancer Institute2006–2010
Quantitative HOX Expression As Prognostic Marker In AMLNational Cancer Institute2004–2006
Molecular-Genetic Analysis Of 3p14 Genomic StabilityNational Cancer Institute1998–2006
Alterations Of E-Cadherin And Proteasome Function In Progression Of Lung CancerNational Cancer Institute2003
Quantitative HOX Expression As Prognostic Marker In AMLNational Cancer Institute2002
Core--Dna Sequencing And AnalysisNational Cancer Institute2001–2002
Core--Dna SequencingNational Cancer Institute1996–2000
Chromosome 3p211 RegionNational Cancer Institute1995–1997
Characterization Of AML1/ETO Genes In T(8;21) Acute Myelogenous LeukemiaEunice Kennedy Shriver National Institute Of Child Health &Human Development1993–1997
Physical MAP And Contigs For Human Chromosome 3National Human Genome Research Institute1991–1996
Characterization Of The Chromosome 3p14 3p21.1 RegionEunice Kennedy Shriver National Institute Of Child Health &Human Development1991–1994
Rearrangement In Human Leukkemia And Physical MappingEunice Kennedy Shriver National Institute Of Child Health &Human Development1988–1992
Construction Of A Physical MAP For Human Chromosome 3National Human Genome Research Institute1990
Characterization Of The Chromosome 3p14-21 RegionEunice Kennedy Shriver National Institute Of Child Health &Human Development1988–1990
Construction Of A Physical MAP For Human Chromosome 3National Institute Of General Medical Sciences1988–1989
Molecular Analysis Of Renal Cell Carcinoma Chromosome 3 DeletionNational Center For Research Resources1988
Molecular Analysis Of The Renal Cell Carcinoma ChromosomeNational Center For Research Resources1987
NCI Clinical Investigator Award ProgramNational Cancer Institute1985–1987

Professional Memberships

American Society of Clinical Oncology - ASCO
Member